Table 1.

Characteristics of patients

sUCBT platformHaplo-Cord platformP
No. of patients 135 72  
Age, y   .004 
 Median 33 35  
 Range 16-53 16-64  
Age group, y, no. (%)   .1 
 16-20 26 (19) 7 (10)  
 21-30 37 (27) 17 (24)  
 31-40 38 (28) 20 (28)  
 >40 34 (25) 28 (39)  
Sex, no. (%)   
 Male 78 (58) 42 (58)  
 Female 56 (42) 30 (42)  
Weight, kg   .3 
 Median 70 72  
 Range 37-105 42-111  
Diagnosis, no. (%)   
 AML 74 (55) 45 (63)  
 ALL 61 (45) 27 (37)  
Disease stage at transplant, no. (%)   .1 
 First complete remission 73 (54) 44 (61)  
 Second or beyond complete remission 43 (32) 14 (20)  
 Relapsed or refractory 19 (14)* 14 (20)  
CMV serologic status before transplantation, no. (%)   .4 
 Positive 108 (80) 55 (86)  
 Negative 27 (20) 9 (14)  
Time of follow-up of surviving patients, mo   .4 
 Median 66 51  
 Range 9-127 15-116  
sUCBT platformHaplo-Cord platformP
No. of patients 135 72  
Age, y   .004 
 Median 33 35  
 Range 16-53 16-64  
Age group, y, no. (%)   .1 
 16-20 26 (19) 7 (10)  
 21-30 37 (27) 17 (24)  
 31-40 38 (28) 20 (28)  
 >40 34 (25) 28 (39)  
Sex, no. (%)   
 Male 78 (58) 42 (58)  
 Female 56 (42) 30 (42)  
Weight, kg   .3 
 Median 70 72  
 Range 37-105 42-111  
Diagnosis, no. (%)   
 AML 74 (55) 45 (63)  
 ALL 61 (45) 27 (37)  
Disease stage at transplant, no. (%)   .1 
 First complete remission 73 (54) 44 (61)  
 Second or beyond complete remission 43 (32) 14 (20)  
 Relapsed or refractory 19 (14)* 14 (20)  
CMV serologic status before transplantation, no. (%)   .4 
 Positive 108 (80) 55 (86)  
 Negative 27 (20) 9 (14)  
Time of follow-up of surviving patients, mo   .4 
 Median 66 51  
 Range 9-127 15-116  

Percentages may not sum to 100 because of rounding.

CMV, cytomegalovirus.

*

Primary refractory = 12; first refractory relapse = 4; and second refractory relapse = 3.

Primary refractory = 11; first refractory relapse = 2; and second refractory relapse = 1.

Close Modal

or Create an Account

Close Modal
Close Modal